Tests a new drug combination with chemotherapy for extensive-stage small cell lung cancer
Compares a new drug combination with standard treatment in adults with small cell lung cancer.
Plain-language title generated from the registry record
Registry title: A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Key facts
- Where
- Athens, Larissa, and Thessaloniki, GreeceSee the 5 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with extensive-stage small cell lung cancer who have not yet had treatment for it and are well enough to do normal activities with little or no help.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Extensive-stage small cell lung cancer (ES-SCLC)
- Earlier treatment
- Cannot have already received certain types of treatment for extensive-stage small cell lung cancer
Main reasons for not taking part
- Certain earlier treatment for extensive-stage small cell lung cancer
- Cancer that has spread to the brain and is causing symptoms
- Certain lung diseases, heart diseases, infections or autoimmune diseases
- Other cancers
- Peripheral sensory neuropathy (a type of nerve damage)
Read by machine on 11 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Which best describes your lung cancer?
- Has the cancer spread to other parts of the body, or is it too advanced to be removed by surgery?
- Can you look after yourself and are you up and about most of the day?
- Has your cancer spread to the brain?
Source: NCT06646276, who can take part
Where in Greece
- Henry Dunant Hospital CenterAthens, GreeceNo longer taking part
- Thoracic General Hospital of Athens "I Sotiria"Athens, GreeceNo longer taking part
- General University Hospital of LarissaLarissa, GreeceNo longer taking part
- Athens Medical Center S.A.Thessaloniki, GreeceNo longer taking part
- Theageneio Cancer HospitalThessaloniki, GreeceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT06646276EU 2024-515740-23-00
- Record updated
- 10 November 2026
- Original description
The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.Read full original descriptionShow less
A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (Atigotatug+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.
Inclusion: Participants must have diagnosis of Extensive-Stage Small Cell Lung Cancer (ES-SCLC); Participants must be Healthy enough to do their normal activities with little or no help based on the ECOG performance scale; Participants must have at least one tumor that can be measured using special imaging techniques like a CT scan or MRI at a site other than the brain and nervous system.
Exclusion: Participants have already received certain types of treatment for extensive stage small cell lung cancer; Participants have certain health conditions, like spread of small cell lung cancer to the brain that are causing symptoms, certain lung diseases, heart diseases, infections, autoimmune diseases, other cancers, or a type of nerve damage called peripheral sensory neuropathy; Other protocol-defined Inclusion/Exclusion criteria apply.